173 related articles for article (PubMed ID: 24123052)
21. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer.
Amirghofran Z; Monabati A; Gholijani N
Pathol Oncol Res; 2004; 10(1):37-41. PubMed ID: 15029260
[TBL] [Abstract][Full Text] [Related]
23. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.
Simak R; Capodieci P; Cohen DW; Fair WR; Scher H; Melamed J; Drobnjak M; Heston WD; Stix U; Steiner G; Cordon-Cardo C
Histol Histopathol; 2000 Apr; 15(2):365-74. PubMed ID: 10809354
[TBL] [Abstract][Full Text] [Related]
24. Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.
Zhang CY; Zhu Y; Rui WB; Dai J; Shen ZJ
Asian J Androl; 2015; 17(1):106-10. PubMed ID: 25219913
[TBL] [Abstract][Full Text] [Related]
25. p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression.
Ferronika P; Triningsih FX; Ghozali A; Moeljono A; Rahmayanti S; Shadrina AN; Naim AE; Wudexi I; Arnurisa AM; Nanwani ST; Harijadi A
Asian Pac J Cancer Prev; 2012; 13(5):1943-8. PubMed ID: 22901151
[TBL] [Abstract][Full Text] [Related]
26. Expression and sub-cellular localization of the CCAAT/enhancer binding protein alpha in relation to postnatal development and malignancy of the prostate.
Zhang J; Wilkinson JE; Gonit M; Keck R; Selman S; Ratnam M
Prostate; 2008 Aug; 68(11):1206-14. PubMed ID: 18481268
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
Hasby EA; Saied EM
J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
[TBL] [Abstract][Full Text] [Related]
28. Progesterone Receptor Expression in the Benign Prostatic Hyperplasia and Prostate Cancer Tissues, Relation with Transcription, Growth Factors, Hormone Reception and Components of the AKT/mTOR Signaling Pathway.
Spirina LV; Kovaleva IV; Usynin EA; Goorbunov AK; Kondakova IV
Asian Pac J Cancer Prev; 2020 Feb; 21(2):423-429. PubMed ID: 32102520
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Significance of High Androgen Receptor Expression in Prostatic Acinar Adenocarcinoma.
Hashmi AA; Mudassir G; Irfan M; Hussain ZF; Hashmi SK; Asif H; Nisar L; Naeem M; Faridi N
Asian Pac J Cancer Prev; 2019 Mar; 20(3):893-896. PubMed ID: 30912411
[TBL] [Abstract][Full Text] [Related]
30. The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance.
Al Fayi MS; Gou X; Forootan SS; Al-Jameel W; Bao Z; Rudland PR; Cornford PA; Hussain SA; Ke Y
Oncotarget; 2016 Dec; 7(50):82783-82797. PubMed ID: 27779102
[TBL] [Abstract][Full Text] [Related]
31. Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer.
Thomas LN; Merrimen J; Bell DG; Rendon R; Too CK
Prostate; 2015 Nov; 75(15):1726-36. PubMed ID: 26202060
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of Endothelial Cell-Specific Molecule 1 Correlates with Gleason Score and Expression of Androgen Receptor in Prostate Carcinoma.
Lai CY; Chen CM; Hsu WH; Hsieh YH; Liu CJ
Int J Med Sci; 2017; 14(12):1263-1267. PubMed ID: 29104483
[TBL] [Abstract][Full Text] [Related]
33. SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation.
Heebøll S; Borre M; Ottosen PD; Andersen CL; Mansilla F; Dyrskjøt L; Orntoft TF; Tørring N
Histol Histopathol; 2008 Sep; 23(9):1069-76. PubMed ID: 18581278
[TBL] [Abstract][Full Text] [Related]
34. ING3 promotes prostate cancer growth by activating the androgen receptor.
Nabbi A; McClurg UL; Thalappilly S; Almami A; Mobahat M; Bismar TA; Binda O; Riabowol KT
BMC Med; 2017 May; 15(1):103. PubMed ID: 28511652
[TBL] [Abstract][Full Text] [Related]
35. Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer.
Okabayashi K; Fujita T; Miyazaki J; Okada T; Iwata T; Hirao N; Noji S; Tsukamoto N; Goshima N; Hasegawa H; Takeuchi H; Ueda M; Kitagawa Y; Kawakami Y
Cancer Sci; 2012 Sep; 103(9):1617-24. PubMed ID: 22676270
[TBL] [Abstract][Full Text] [Related]
36. Myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer.
Saidova AA; Potashnikova DM; Tvorogova AV; Paklina OV; Veliev EI; Knyshinsky GV; Setdikova GR; Rotin DL; Maly IV; Hofmann WA; Vorobjev IA
PLoS One; 2021; 16(5):e0251961. PubMed ID: 34019593
[TBL] [Abstract][Full Text] [Related]
37. Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer.
Romics I; Bánfi G; Székely E; Krenács T; Szende B
Pathol Oncol Res; 2008 Sep; 14(3):307-11. PubMed ID: 18415709
[TBL] [Abstract][Full Text] [Related]
38. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.
Karpf AR; Bai S; James SR; Mohler JL; Wilson EM
Mol Cancer Res; 2009 Apr; 7(4):523-35. PubMed ID: 19372581
[TBL] [Abstract][Full Text] [Related]
39. Possible prognostic value of BORIS transcript variants ratio in laryngeal squamous cell carcinomas - a pilot study.
Novak Kujundžić R; Grbeša I; Ivkić M; Krušlin B; Konjevoda P; Gall Trošelj K
Pathol Oncol Res; 2014 Jul; 20(3):687-95. PubMed ID: 24563233
[TBL] [Abstract][Full Text] [Related]
40. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
